Amy Schulman is a Managing Partner at Polaris Partners, a venture capital firm, and co-founder of the Polaris Innovation Fund. She currently serves as executive chair of Lyndra Therapeutics, which she co-founded and served as the company's initial CEO. She chairs the board of directors of Alnylam Pharmaceuticals (Nasdaq: ALNY), is on the board of trustees at Mount Sinai Hospital where she co-chairs the Innovations Committee, is a member of Singapore's Health and Biomedical Sciences International Advisory Council, is a member of the LifeSci NYC Advisory Council and was a Senior Lecturer at Harvard Business School. She represents Polaris as a director of Kallyope, Volastra, Thirty Madison, ByHeart and SQZ Biotech. When Amy joined Polaris in 2014, she became CEO of Arsia Therapeutics, later acquired by Eagle Pharmaceuticals. Prior to Polaris, Amy spent several years at Pfizer as executive vice president and general counsel and president of Pfizer Nutrition, and later as president of Pfizer Consumer Healthcare. Amy has received numerous awards including Xconomy's Newcomer Award, Scientific American's Worldview 100 List, Fierce Biotech's Top 15 Women in Biotech, and Fortune Magazine's 50 Most Powerful Women in Business. She is a Phi Beta Kappa graduate of Wesleyan University with a joint degree in philosophy and english and earned her J.D. from Yale Law School.
Standing Committees: Governance and Nominating; Investment
